Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00762801
Recruitment Status : Withdrawn (Principal Investigator left institution.)
First Posted : September 30, 2008
Last Update Posted : October 26, 2016
Sponsor:
Information provided by (Responsible Party):
University of North Texas Health Science Center

Brief Summary:
RLIP76 (Ral binding protein1) is a 76 kDa splice variant protein encoded by the human gene (RALBP1, 18p11.22). It is a multifunctional modular protein found ubiquitously from Drosophila to humans, in cells ranging from red blood cells to endothelial cells of the brain. Its expression more predominant in breast, heart, liver and less so in colon and brain parenchyma.

Condition or disease
Healthy

Detailed Description:
RLIP76 is shown to be over expressed in a variety of cancer cells. However, no study has yet been done on its expression on normal cells. The studies proposed in this project will study the expression of RLIP76 in blood cells of healthy human subjects in the population of North Texas region.

Layout table for study information
Study Type : Observational
Actual Enrollment : 0 participants
Time Perspective: Prospective
Official Title: Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects
Study Start Date : September 2008
Actual Primary Completion Date : September 2011
Actual Study Completion Date : September 2011



Primary Outcome Measures :
  1. Expression of RLIP76 in red blood cells and white blood cells of 100 healthy human subjects. [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. To investigate the RLIP76 mediated transport of glutathione conjugates and chemotherapeutic drugs. [ Time Frame: 3 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
100 healthy volunteers
Criteria

Inclusion Criteria:

  • Healthy as defined by lack of serious health conditions or diseases

Exclusion Criteria:

  • Children, pregnant women, prisoners, persons with any medical condition that precludes phlebotomy and persons unwilling or unable to provide consent will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00762801


Locations
Layout table for location information
United States, Texas
University of North Texas Health Science Center
Fort Worth, Texas, United States, 76107
University of North Texas Health Science Center
Fort Worth, Texas, United States, 76109
Sponsors and Collaborators
University of North Texas Health Science Center
Investigators
Layout table for investigator information
Principal Investigator: Sanjay Awasthi, MD University of North Texas Health Science Center
Publications of Results:

Other Publications:
Layout table for additonal information
Responsible Party: University of North Texas Health Science Center
ClinicalTrials.gov Identifier: NCT00762801    
Other Study ID Numbers: 2008-32
First Posted: September 30, 2008    Key Record Dates
Last Update Posted: October 26, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by University of North Texas Health Science Center:
RLIP76
Cancer
apoptosis